The two companies ARPA-H has just funded to work on ibogaine are an ibogaine clinic in Cancún, Mexico, and the Dallas company Mark Cuban founded to sell generic prescriptions at cost.
Neither is a drug developer in the ordinary sense. Beond, Inc. treats patients with a Schedule I drug in a country where that is legal. Mark Cuban Cost Plus Drug Company, PBC, built its business on pricing transparency, not on investigational new drug applications. On November 12 the Department of Health and Human Services named them the first two performers the Advanced Research Projects Agency for Health has funded to work on ibogaine itself, rather than on measurement across several therapies.
Both awards are aimed at PTSD, in a year when almost everything visible in the federal ibogaine effort pointed at opioid addiction. That is the second odd thing here, and it takes longer to explain.
The first is stranger on the surface than underneath. Five weeks before the announcement, the FDA had written down what the published ibogaine record was missing, and there were two things on the list.
What FDA said was missing
In a request for information on the design of early-phase ibogaine trials, published in the Federal Register on October 6, the agency wrote that published ibogaine studies mostly lack participant-level data and adequate characterization of the product that was given, including its dose, purity and potency. This desk read that notice as a cardiology protocol in all but name.
Beond holds material of the first kind. Cost Plus is funded to make the second. Neither is a clean fit: Beond’s records were never a study, and a gap in the published record is not closed by a dataset that was never published.
Beond received an award of up to $800,000 that began on October 29, titled the Ibogaine Data Project. The company says it covers de-identified records from 250 patients it has already treated. Cost Plus received up to $4.2 million beginning November 10, to establish what ARPA-H calls the regulatory, clinical, chemical and engineering foundation for a domestically manufactured, single-molecule ibogaine hydrochloride product for potential PTSD treatment. Both are ceilings, not amounts paid. ARPA-H’s stated commitment for the effort is up to $4.9 million over five years, with payments contingent on milestones, which HHS calls an initial figure against which further awards are expected.
The fit invites a causal story the record does not support. Neither agency has said the awards were shaped to the October notice, and the chronology argues against it: ARPA-H’s description of the Cost Plus project refers to the state of the field as of September 2026, before the notice published. This is one department working from the same information at the same time.
HHS was precise about what the money does. The ARPA-H efforts, it says, “support preparation of Investigational New Drug Applications (INDs) to enable future clinical trials in the United States, secure clinical-grade ibogaine, and develop processes for sustainable domestic manufacturing.” The same release draws the line: the awards “fund the regulatory and manufacturing groundwork for future trials,” and do “not fund treatment of patients or human-subject research” or “authorize clinical trials.”
What a clinic in Cancún can hand over
Beond’s contribution is an existing dataset. The company says it will deliver de-identified records from 250 patients treated at its Cancún facility, covering safety including electrocardiogram data and any adverse events, alongside how those patients’ addiction, PTSD and depression symptoms changed. Beond also says every patient received ibogaine alone with no other psychedelic combined and consented to the use of their data, and that the ibogaine is backed by certificates of analysis, the supplier documents recording a batch’s identity and purity. Those are not the dose, purity and potency characterization FDA described for trial product, but they are the second gap’s kind of evidence arriving with the first gap’s award.
A clinic handing over records it already holds is a retrospective case series assembled by the party that delivered the treatment: no protocol, no randomization, no comparator, no prespecified endpoint. That is what HHS’s sentence about not funding human-subject research describes. It is also the kind of patient-level material FDA said the evidence base lacked. ARPA-H’s chief medical officer, Rafid Fadul, framed its use narrowly in Beond’s announcement: starting from real-world clinical experience, he said, helps design ibogaine trials that protect patients and reach a clear answer sooner. The dataset is an input to trial design.
Two things will shape what the 250 records can support. Beond says it has completed approximately 6,000 treatments and cared for thousands of patients, without giving a patient total, so the delivered set is a fraction of its clinical experience that the release does not let anyone size. Neither party has said how those 250 were chosen, and selection criteria are the first question anyone asks of a retrospective safety series. The second is the ECGs. Ibogaine’s documented serious risk is QT prolongation and the arrhythmia that can follow, and a cardiac dataset from patients dosed under physician supervision is a different object from a published case report.
Which raises why the records had to come from Mexico. On ClinicalTrials.gov, checked on November 13, the completed interventional ibogaine studies are in the United Kingdom, Spain and Brazil, and every United States entry that has enrolled a participant is observational. One of them, a University of California, Irvine neuroimaging study, states in its own registry record that participants “will already be independently scheduled to receive legal ibogaine treatment at a licensed clinic outside of the U.S.” The public registry therefore shows U.S. researchers observing ibogaine exposure generated outside the country, not an enrolled U.S. interventional dataset.
What Dallas is funded to do, and what sits above it
Making ibogaine in the United States requires more than a contract. A manufacturer or importer must hold a Drug Enforcement Administration registration for that Schedule I drug code, and applications for those registrations are published in the Federal Register for objection. Nine companies have filed bulk-manufacturer applications naming ibogaine since the start of 2025, among them Benuvia Operations and Purisys. Four of the nine are analytical-standards houses, whose quantities are not a clinical supply. Neither performer is among any of them.
That is unremarkable this early. ARPA-H describes the project as “a design and Investigational New Drug clinical research phase,” which does not require a registration on day one, and a registration can sit with a contract manufacturer. It does mean the step from a funded chemistry program to ibogaine lawfully made in the United States is still ahead.
Supply sits one layer further out. The DEA has proposed raising the 2027 national ibogaine production ceiling to 12,002 grams from the 210 grams it established for 2026, with comments closing on December 10. Until a final order, 210 grams remains the operative ceiling, and a ceiling is not a supply: it is shared across every registered manufacturer and sits above registration and individual quota, neither of which is public for ibogaine.
How the pathway assembled itself
None of this began on November 12. Read in order, the year shows a system acquiring one layer at a time.
1990s · An application existed once
The University of Miami held an ibogaine investigational new drug application, filed from Deborah Mash’s program, so the compound had been examined under FDA oversight once. Public accounts date it to 1993 or 1994 and fix neither its scope nor its fate.
April 14, 2026 · Measurement
The first ARPA-H award to name ibogaine, up to $4 million to INVI MindHealth of Denver under its EVIDENT initiative, funded measurement in veterans, with deidentified data going to the agency’s own repository. No drug, no protocol, no site. It began four days before Executive Order 14401, the April directive that names ibogaine twice and that HHS says the November announcement advances.
June 15, 2026 · A hospital
NIDA’s cooperative agreement sent about $2.29 million in its first year to Brigham and Women’s, putting federal ibogaine money inside a hospital. The design FDA would describe four months later is a hospital study. This one is in opioid use disorder.
July and August 2026 · An agenda, a returned file, a solicitation
Six federal bodies moved in a single coordinated release in July: NIDA revived older ibogaine data for FDA, and ARPA-H opened an ibogaine funding competition, which it posted in August as ASCENT-IBO, confined to treatment-resistant or high-mortality opioid use disorder. Also in August, the President announced that the University of Miami had given the federal government its ibogaine application. No agency has published what was transferred or its standing, and MAPS said the file “is not a substitute for current safety and sourcing data.”
October 6, 2026 · The requirements, in writing
Beyond the two evidence gaps, FDA’s notice made the rest of the design legible: the dose ceiling, the cardiac unit, the genotype screen, the oversight bodies. A single-site Phase 1/2a registration in Basalt, Colorado appeared a week later. Neither binds anyone, and no participant has been dosed.
November 2026 · The two gaps funded
Alongside the two awards, DEA proposed a larger 2027 ibogaine ceiling on November 10, the day the Cost Plus award began. The proposal names no award, no performer and no program, and runs on a schedule the agency sets itself. It cites Executive Order 14401 and the same indication: a shared policy environment, not a response to these awards.
PTSD, not opioids
Which brings back the second oddity. Almost everything visible in the federal ibogaine effort before November pointed at opioid use disorder, and both awards went to PTSD.
NIDA’s funded hospital program is in opioid use disorder. ASCENT-IBO, the ARPA-H solicitation posted in August, is restricted to opioid use disorder that is treatment-resistant or carries elevated mortality risk. And the FDA notice spends its most difficult passage there. That passage asks the public how a participant should be taken off methadone or buprenorphine, medications that lower their risk of death, before receiving a single investigational dose. FDA proposes no answer.
Neither HHS nor ARPA-H has said why PTSD came first. The available record offers one explanation: a PTSD trial does not have to solve it. The population FDA describes, adults who have not responded to an SSRI and trauma-focused therapy, raises nothing like the ethical problem of withdrawing agonist treatment from someone whose risk of dying goes up when you do. Of the two indications, the one with the clearer federal rationale is also the one with a design problem FDA has publicly left unresolved.
The efficacy case for PTSD is thinner than the attention it gets. The ibogaine evidence in veterans is observational, and the study behind the attention is a Stanford study of 30 male Special Operations veterans with mostly mild traumatic brain injury, published in Nature Medicine in 2024, which reported large improvements from baseline in disability, PTSD, depression and anxiety a month after a single magnesium-ibogaine treatment, in an observational design with no control group; its authors wrote that controlled trials are needed to validate those open-label findings. A 12-month follow-up in Translational Psychiatry in August found the improvements sustained in the 25 participants who completed it, while noting that most used other psychedelics or pursued other treatments during the year.
Which surfaces a seam between the two layers the awards fund. That regimen was magnesium-ibogaine, where the magnesium is there for a cardiac reason. Cost Plus is funded to make single-molecule ibogaine hydrochloride. The strongest human signal and the funded domestic product are not the same regimen.
The opioid indication is behind PTSD in the funding sequence, not out of it. HHS said on November 12 that additional ARPA-H awards are expected with a focus on ibogaine for substance use disorders, and that the agency is “pursuing multiple IND applications across more than one indication” instead of betting on a single path. ARPA-H says it is evaluating proposals for ASCENT-IBO. Those are stated plans, not filings, and they are the clearest signal so far that the harder indication is queued.
The milestone that comes next
Seven months of federal money have assembled the inputs. The pathway now has measurement, clinical data, a funded chemistry program and a proposed ceiling. What it does not have is an investigational new drug application in effect for ibogaine itself: ARPA-H said in November that none exists for ibogaine as a treatment for psychiatric conditions in the United States. That is the one thing the 1990s file suggests once existed.
That is not something an award can deliver. An IND takes effect thirty days after FDA receives it, unless the agency acts first, and it needs a sponsor willing to hold it, product made under a DEA registration and an individual quota, and a hospital able to manage a life-threatening arrhythmia that is willing to run the protocol. Each is a decision by someone who has not yet publicly made it.
So the thing to watch is not the next award. It is the first name attached to an IND.